
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.23 | 0.750407830343 | 30.65 | 31.4964 | 29.73 | 1312898 | 30.97652081 | CS |
4 | 1.97 | 6.81425112418 | 28.91 | 34.58 | 28.44 | 1693124 | 32.15562745 | CS |
12 | -4.47 | -12.6449787836 | 35.35 | 35.78 | 27.24 | 2064309 | 31.32988473 | CS |
26 | 6.14 | 24.8181083266 | 24.74 | 36.84 | 21.11 | 2935358 | 27.63467527 | CS |
52 | 17.87 | 137.355880092 | 13.01 | 36.84 | 12.84 | 3115140 | 22.16419982 | CS |
156 | 20.54 | 198.646034816 | 10.34 | 36.84 | 3.48 | 3835960 | 15.43540976 | CS |
260 | 15.11 | 95.8148383006 | 15.77 | 56.74 | 3.48 | 3015051 | 18.14750832 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions